Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review

World Journal of Gastroenterology

Volumn 19, Issue 17, 2013, Pages 2591-2602

  Marchioni, Renée M ^a   Lichtenstein, Gary R ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adalimumab; Certolizumab; Congenital abnormalities; Infliximab; Inhibitors; Pregnancy; Safety; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CROHN DISEASE; FETUS RISK; HUMAN; LIVE BIRTH; LOW BIRTH WEIGHT; NONHUMAN; PREGNANCY; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; SMALL FOR DATE INFANT; SPONTANEOUS ABORTION; STILLBIRTH; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

EID: 84877348798     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i17.2591     Document Type: Article

References (105)

1. Munkholm P. Crohn's disease--occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull 1997; 44: 287-302 [PMID: 9233548]
2. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 255-281, vii [PMID: 10372268]
3. Moscandrew M, Kane S. Inflammatory bowel diseases and management considerations: fertility and pregnancy. Curr Gastroenterol Rep 2009; 11: 395-399 [PMID: 19765367]
4. Leimkühler AM. [Psychosocial after care: studies of the value of psychosocial measures in clinical practice]. Fortschr Neurol Psychiatr 1990; 58: 301-309 [PMID: 2172128]
5. Centers for Disease Control offcial website. Available from: URL: http://www.cdc.gov/reproductivehealth
6. Tartakovsky B, Ben-Yair E. Cytokines modulate preim-plantation development and pregnancy. Dev Biol 1991; 146: 345-352 [PMID: 1864460 DOI: 10.1016/0012-1606(91)90236-V]
7. Imseis HM, Zimmerman PD, Samuels P, Kniss DA. Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in frst trimester trophoblasts: suppression by glu-cocorticoids and NSAIDs. Placenta 1997; 18: 521-526 [PMID: 9290146 DOI: 10.1016/0143-4004(77)90005-4]
8. Daher S, Fonseca F, Ribeiro OG, Musatti CC, Gerbase-De-Lima M. Tumor necrosis factor during pregnancy and at the onset of labor and spontaneous abortion. Eur J Obstet Gynecol Reprod Biol 1999; 83: 77-79 [PMID: 10221614 DOI: 10.1016/ S0301-2115(98)00252-8]
9. Yu XW, Yan CF, Jin H, Li X. Tumor necrosis factor receptor 1 expression and early spontaneous abortion. Int J Gynaecol Obstet 2005; 88: 44-48 [PMID: 15617704 DOI: 10.1016/j.ijgo.2004.08.020]
10. Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 2010; 24 Suppl 1: 3-14 [PMID: 21175228 DOI: 10.2165/1158290-000000000-00000]
11. Reimund JM, Wittersheim C, Dumont S, Muller CD, Bau-mann R, Poindron P, Duclos B. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996; 16: 144-150 [PMID: 8734357 DOI: 10.1007/BF01540912]
12. Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, Poindron P, Duclos B. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and inter-leukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996; 39: 684-689 [PMID: 9026483 DOI: 10.1136/gut.39.5.684]
13. Riegel D, Büermann L, Gross KD, Luszik-Bhadra M, Mishra SN. Existence and stability of magnetic 3d moments in noble- and transition-metal hosts. Phys Rev Lett 1989; 62: 316-319 [PMID: 10040201 DOI: 10.1053/gast.2000.18160]
14. Infliximab (Remicade) package insert. Johnson & Johnson. Malvern: Centocor Ortho Biotech, 2005. Available from: URL: http://www.remicade.com
15. Adalimumab (Humira) package insert. North Chicago: Abbott Laboratories, 2007. Available from: URL: http://www. humira.com
16. Certolizumab pegol (Cimzia) package insert. Smyrna: UCB, 2008. Available from: URL: http://www.cimzia.com
17. Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gas-troenterol 2011; 106: 214-223; quiz 224 [PMID: 21157441 DOI:10.1038/ajg.2010.464]
18. Chambers CD, Johnson DL, Jones KL. Pregnancy outcome in women exposed to anti-TNF medications: the OTIS Rheumatoid Arthritis in Pregnancy Study. Arthritis Rheum 2004; 50: S479
19. Mahadevan U, Terdiman JP, Church J. Infiximab levels in infants born to women with inflammatory bowel disease. Gastroenterol 2007; 132: A144
20. Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Lioté F, Goeb V, Azaïs I, Martin A, Pallot-Prades B, Maugars Y, Mariette X. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 2009; 76: 28-34 [PMID: 19059799 DOI: 10.1016/ j.jbspin.2008.04.016]
21. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003; 30: 241-246 [PMID: 12563675]
22. Correia LM, Bonilha DQ, Ramos JD, Ambrogini O, Misz-puten SJ. Inflammatory bowel disease and pregnancy: report of two cases treated with infiximab and a review of the literature. Eur J Gastroenterol Hepatol 2010; 22: 1260-1264 [PMID: 20671559 DOI: 10.1097/MEG.0b013e28329543a]
23. Hyrich KL, Symmons DP, Watson KD, Silman AJ. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 2006; 54: 2701-2702 [PMID: 16871549 DOI: 10.1002/art.22028]
24. Kane S, Ford J, Cohen R, Wagner C. Absence of infiximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009; 43: 613-616 [PMID: 19142167 DOI: 10.10.1097/MCG.0b013e31817f9367]
25. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lich-tenstein GR. Outcome of pregnancy in women receiving infiximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385-2392 [PMID: 15571587 DOI: 10.1111/j.172-0241.2004.30186.x]
26. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infiximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005; 21: 733-738 [PMID: 15771759 DOI: 10.1111/j.1365-2036.2005.02405.x]
27. Rosner I, Haddad A, Boulman N, Feld J, Avshovich N, Slobodin G, Rozenbaum M. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46: 1508; author reply 1508-1509 [PMID: 17684027 DOI: 10.1093/rheumatology/ kem068]
28. Schnitzler F, Fickler HH, Ferrante M, Noman M, Van Assche GA, Spitz B, Vermeire S, Rutgeerts P. Intentional treatment with infiximab during pregnancy in women with infamma-tory bowel disease. Gastroenterol 2007; 132: A144
29. Weber-Schoendorfer C, Fritzsche J, Schaefer. Pregnancy outcomes in women exposed to adalimumab or infiximab: The experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Reprod Toxicol 2011; 31: A267-268 [DOI: 10.1016/j.reprotox.2010.12.052]
30. Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Peppelenbosch MP, van der Woude CJ. High intra-uterine exposure to infiximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011; 33: 1053-1058 [PMID: 21366638 DOI: 10.1111/j.1365-2036.2011.04617.x]
31. Akinci A, Ozçakar L. Infiximab use during pregnancy revisited. Acta Reumatol Port 2008; 33: 374-375 [PMID: 18846021]
32. Angelucci E, Cesarini M, Vernia P. Inadvertent conception during concomitant treatment with infliximab and metho-trexate in a patient with Crohn's disease: is the game worth the candle? Inflamm Bowel Dis 2010; 16: 1641-1642 [PMID:20186946 DOI: 10.1002/ibd.21226]
33. Angelucci E, Cocco A, Viscido A, Caprilli R. Safe use of infliximab for the treatment of fstulizing Crohn's disease during pregnancy within 3 months of conception. Infamm Bowel Dis 2008; 14: 435-436 [PMID: 18050300 DOI: 10.1002/ibd.20319]
34. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, Kalden-Nemeth D, Kalden JR, Manger B. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002; 47: 506-512 [PMID: 12382299 DOI: 10.1002/art.10671]
35. Arai K, Takeuchi Y, Oishi C, Imawari M. The impact of disease activity of Crohn's disease during pregnancy on fetal growth. Clin J Gastroenterol 2010; 3: 179-181 [DOI: 10.1007/ s12328-010-0158-9]
36. Aratari A, Margagnoni G, Koch M, Papi C. Intentional inf-liximab use during pregnancy for severe steroid-refractory ulcerative colitis. J Crohns Colitis 2011; 5: 262 [PMID: 21575893 DOI: 10.1016/j.crohns.2011.02.004]
37. Burt MJ, Frizelle FA, Barbezat GO. Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody). J Gastroenterol Hepatol 2003; 18: 465-466 [PMID: 12653902 DOI: 10.1046/j.1440-1746.2003.02983.x]
38. Chaparro M, Gisbert JP. Successful use of infiximab for peri-anal Crohn's disease in pregnancy. Infamm Bowel Dis 2011; 17: 868-869 [PMID: 20564533 DOI: 10.1002/ibd.21368]
39. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010; 4: 603-605 [PMID: 21122568 DOI: 10.1016/ j.crohns.2010.05.001]
40. Epping G, van der Valk PD, Hendrix R. Legionella pneu-mophila pneumonia in a pregnant woman treated with anti-TNF-α antibodies for Crohn's disease: a case report. J Crohns Colitis 2010; 4: 687-689 [PMID: 21122583 DOI: 10.1016/ j.crohns.2010.08.006]
41. Hou JK, Mahadevan U. A 24-year-old pregnant woman with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009; 7: 944-947 [PMID: 19410016 DOI: 10.1016/j.cgh.2009.04.022]
42. James RL, Pearson LL. Successful treatment of pregnancy-triggered Crohn's disease complicated by severe recurrent life-threatening gastrointestinal bleeding. Am J Gastroenterol 2001; 96: S295 [DOI: 10.1016/S0002-9270(01)03714-5]
43. Kinder AJ, Edwards J, Samanta A, Nichol F. Pregnancy in a rheumatoid arthritis patient on infiximab and methotrexate. Rheumatology (Oxford) 2004; 43: 1195-1196 [PMID: 15317958 DOI: 10.1093/rheumatology/keh264]
44. Østensen M, Raio L. A woman with rheumatoid arthritis whose condition did not improve during pregnancy. Nat Clin Pract Rheumatol 2005; 1: 111-114; quiz 1 p. following 114 [PMID: 16932640 DOI: 10.1038/ncprheum0044]
45. Puig L, Barco D, Alomar A. Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology 2010; 220: 71-76 [PMID: 19940453 DOI: 10.1159/000262284]
46. Srinivasan R. Infiximab treatment and pregnancy outcome in active Crohn's disease. Am J Gastroenterol 2001; 96: 2274-2275 [PMID: 11467677 DOI: 10.1016/S0002-9270(01)02550-3]
47. Steenholdt C, Al-Khalaf M, Ainsworth MA, Brynskov J. Therapeutic infiximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohns Colitis 2012; 6: 358-361 [PMID: 22405174 DOI: 10.1016/ j.crohns.2011.10.002]
48. Stengel JZ, Arnold HL. Is infiximab safe to use while breastfeeding? World J Gastroenterol 2008; 14: 3085-3087 [PMID: 18494064 DOI: 10.3748/wjg.14.3085]
49. Tursi A. Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease. Dig Liver Dis 2006; 38: 439-440 [PMID: 16563889 DOI: 10.1016/j.dld.2006.01.017]
50. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4: 1255-1258 [PMID: 17045211 DOI: 10.1016/j.cgh.2006.07.018]
51. Wibaux C, Andrei I, Paccou J, Philippe P, Biver E, Duques-noy B, Flipo RM. Pregnancy during TNFalpha antagonist therapy: beware the rifampin-oral contraceptive interaction. Report of two cases. Joint Bone Spine 2010; 77: 268-270 [PMID: 20447852 DOI: 10.1016/j.jbspin.2010.02.001]
52. Xirouchakis E, Karantanos P, Tsartsali L, Karkatzos E. Pregnancy and Crohn's disease: Infliximab induction therapy, accidental conception, pregnancy outcome and postpartum complications. Annals Gastroenterol 2006; 19: 138-140
53. Johnson DJ, Jones KL, Chambers CD, Salas E. Pregnancy outcomes in women exposed to Adalimumab: The OTIS Autoimmune Diseases in Pregnancy Project. Gastroenterol 2009; 136 S1: A27 [DOI: 10.1016/S0016-5085(09)60125-6]
54. Johnson DL, Jones KL, Jimenez J, Mirrasoul N, Salas E, Chambers CD. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Available from: URL: http://www.otispregnancy. org/readResource.php?r=108643
55. Abdul Wahab NA, Harkin R. Humira in pregnancy for Crohn' s disease: A case report. Ir J Med Sci 2011; 180: S132 [DOI: 10.1007/s11845-011-0697-1]
56. Ben-Horin S, Yavzori M, Katz L, Picard O, Fudim E, Chow-ers Y, Lang A. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 2010; 8: 475-476 [PMID: 20005982 DOI: 10.1016/j.cgh.2009.11.023]
57. Bosworth BP, Inra J, Eswaran S, Scherl EJ. Failed use of adali-mumab in maintaining remission in Crohn's disease during pregnancy. Am J Gastroenterol 2007; 102: S322 [DOI: 10.1111/ j.1572-0241.2007.01491_7.x]
58. Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 2006; 51: 2045-2047 [PMID: 17009112 DOI: 10.1007/s10620-006-9452-2]
59. Dessinioti C, Stefanaki I, Stratigos AJ, Kostaki M, Katsambas A, Antoniou C. Pregnancy during adalimumab use for psoriasis. J Eur Acad Dermatol Venereol 2011; 25: 738-739 [PMID: 20569288 DOI: 10.1111/j.1468-3083.2010.03756.x]
60. Jürgens M, Brand S, Filik L, Hübener C, Hasbargen U, Beigel F, Tillack C, Göke B, Ochsenkühn T, Seiderer J. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. Infamm Bowel Dis 2010; 16: 1634-1636 [PMID: 20027647 DOI: 10.1002/ibd.21198]
61. Kraemer B, Abele H, Hahn M, Rajab T, Kraemer E, Wall-weiner D, Becker S. A successful pregnancy in a patient with Takayasu's arteritis. Hypertens Pregnancy 2008; 27: 247-252 [PMID: 18696353 DOI: 10.1080/10641950801955741]
62. Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Infamm Bowel Dis 2006; 12: 827-828 [PMID: 16917239 DOI: 10.1097/00054725-200608000-00020]
63. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46: 695-698 [PMID: 17158212 DOI: 10.1093/rheumatol-ogy/kel400]
64. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 2005; 54: 890 [PMID: 15888806 DOI: 10.1136/ gut.2005.065417]
65. Kane SV, Acquah LA. Placental transport of immunoglobu-lins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009; 104: 228-233 [PMID: 19098873 DOI: 10.1038/ajg.2008.71]
66. Mahadevan U, Abreu MT. Certolizumab use in pregnancy: low levels detected in cord blood. Am J Gastroenterol 2009; 136 S5: A-960 [DOI: 10.1016/S0016-5085(09)60658-2]
67. Oussalah A, Bigard MA, Peyrin-Biroulet L. Certolizumab use in pregnancy. Gut 2009; 58: 608 [PMID: 19299393 DOI: 10.1136/gut.2008.166884]
68. Steinberg SA, Ullman TA. Certolizumab treatment of linear IgA dermatosis in a pregnant Crohn's colitis patient: A case study and review of the literature. Gastroenterol 2010; 138: S698 [DOI: 10.1016/S0016-5085(10)63209-X]
69. Ventura SJ, Abma JC, Mosher WD, Henshaw SK. Estimated pregnancy rates for the United States, 1990-2005: an update. Natl Vital Stat Rep 2009; 58: 1-14 [PMID: 20121003]
70. Ventura SJ, Mosher WD, Curtin SC, Abma JC, Henshaw S. Highlights of trends in pregnancies and pregnancy rates by outcome: estimates for the United States, 1976-96. Natl Vital Stat Rep 1999; 47: 1-9 [PMID: 10635682]
71. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Mathews TJ, Osterman MJ. Births: fnal data for 2008. Natl Vital Stat Rep 2010; 59: 1, 3-71 [PMID: 22145497]
72. March of Dimes: Premature Birth; Miscarriage. Available from: URL: http://www.marchofdimes.com
73. Centers for Disease Control: Birth Defects; Low Birth Weight. Available from: URL: http://www.ephtracking.cdc.gov
74. Hudson M, Flett G, Sinclair TS, Brunt PW, Templeton A, Mowat NA. Fertility and pregnancy in infammatory bowel disease. Int J Gynaecol Obstet 1997; 58: 229-237 [PMID: 9252260 DOI: 10.1016/S0020-7292(97)00088-X]
75. Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with infammatory bowel disease: a population-based cohort study. Am J Gastroenterol 2002; 97: 641-648 [PMID: 11926208 DOI: 10.1016/S0002-9270(01)04105-3]
76. Cornish J, Tan E, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP. A meta-analysis on the infuence of infammatory bowel disease on pregnancy. Gut 2007; 56: 830-837 [PMID: 17185356 DOI: 10.1136/gut.2006.108324]
77. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035 [PMID: 9321530 DOI: 10.1056/NEJM199710093371502]
78. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, De-Woody KL, Schaible TF, van Deventer SJ. Infiximab for the treatment of fstulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405 [PMID: 10228190 DOI: 10.1056/ NEJM199905063401804]
79. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 [PMID: 12047962 DOI: 10.1016/ S0140-6736(02)08512-4]
80. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Sch-reiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatment strategies of infiximab in Crohn's disease. Gastro-enterology 2004; 126: 402-413 [PMID: 14762776 DOI: 10.1053/ j.gastro.2003.11.014]
81. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003; 21: 3365-3369 [PMID: 12850341 DOI: 10.1016/S0264-410X(03)00334-7]
82. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimum-ab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333; quiz 591 [PMID: 16472588 DOI: 10.1053/ j.gastro.2005.11.030]
83. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-1239 [PMID: 17299059 DOI: 10.1136/gut.2006.106781]
84. Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastro-enterol 2004; 99: 1984-1989 [PMID: 15447761 DOI: 10.1111/ j.1572-0241.2004.40462.x]
85. Rivkin A. Certolizumab pegol for the management of Crohn' s disease in adults. Clin Ther 2009; 31: 1158-1176 [PMID: 19695385 DOI: 10.1016/j.clinthera.2009.06.015]
86. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A. A randomized, placebo-controlled trial of cer-tolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-818 [PMID: 16143120 DOI: 10.1053/j.gastro.2005.06.064]
87. Nesbitt A, Foulkes R. Placental transfer and accumulation in milk of the anti-TNF antibody TN3 in rats: immunoglobulin G1 versus PEGylated Fab. Am J Gastroenterol 2006; 101: S119
88. Nielsen OH, Andreasson B, Bondesen S, Jacobsen O, Jarnum S. Pregnancy in Crohn's disease. Scand J Gastroenterol 1984; 19: 724-732 [PMID: 6515312]
89. Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983; 18: 735-742 [PMID: 6669937 DOI: 10.3109/00365528309182088]
90. Alstead EM. Inflammatory bowel disease in pregnancy. Postgrad Med J 2002; 78: 23-26 [PMID: 11796867 DOI: 10.1136/ pmj.78.915.23]
91. Korelitz BI. Inflammatory bowel disease and pregnancy. Gastroenterol Clin North Am 1998; 27: 213-224 [PMID: 9546091 DOI: 10.1016/S0889-8553(05)70354-X]
92. Morales M, Berney T, Jenny A, Morel P, Extermann P. Crohn's disease as a risk factor for the outcome of pregnancy. Hepatogastroenterology 2000; 47: 1595-1598 [PMID: 11149010]
93. Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in infammatory bowel disease. J Matern Fetal Neonatal Med 2004; 15: 237-241 [PMID: 15280131 DOI: 10.1080/14767050410 001668662]
94. Bortoli A, Saibeni S, Tatarella M, Prada A, Beretta L, Rivolta R, Politi P, Ravelli P, Imperiali G, Colombo E, Pera A, Daperno M, Carnovali M, de Franchis R, Vecchi M. Pregnancy before and after the diagnosis of infammatory bowel diseases: retrospective case-control study. J Gastroenterol Hepatol 2007; 22: 542-549 [PMID: 17376049]
95. Larzilliere I, Beau P. [Chronic inflammatory bowel disease and pregnancy. Case control study]. Gastroenterol Clin Biol 1998; 22: 1056-1060 [PMID: 10051981]
96. Nørgård B, Puho E, Pedersen L, Czeizel AE, Sørensen HT. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study. Am J Gastroenterol 2003; 98: 2006-2010 [PMID: 14499779 DOI: 10.1111/j.1572-0241.2003.07578.x]
97. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with infamma-tory bowel disease: a large community-based study from Northern California. Gastroenterology 2007; 133: 1106-1112 [PMID: 17764676 DOI: 10.1053/j.gastro.2007.07.019]
98. Stephansson O, Larsson H, Pedersen L, Kieler H, Granath F, Ludvigsson JF, Falconer H, Ekbom A, Sørensen HT, Nør-gaard M. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis 2011; 17: 795-801 [PMID: 20564537 DOI: 10.1002/ibd.21369]
99. Nørgård B, Hundborg HH, Jacobsen BA, Nielsen GL, Fon-ager K. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007; 102: 1947-1954 [PMID: 17573787 DOI: 10.1111/j.1572.0241.2007.01355.x]
100. Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease--a population-based cohort study. Am J Obstet Gynecol 1997; 177: 942-946 [PMID: 9369849]
101. Fonager K, Sørensen HT, Olsen J, Dahlerup JF, Rasmussen SN. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 1998; 93: 2426-2430 [PMID: 9860403 DOI: 10.1111/j.1572-0241.1998.00698.x]
102. Mahadevan U, Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenter-ology 2006; 131: 278-282 [PMID: 16831610 DOI: 10.1053/ j.gastro.2006.04.048]
103. Seirafi M, Treton X, De Vroey B, Cosnes J, Roblin X, Allez M, Marteau P, De Vos M, Flamant M, Laharie D, Savoye G, Peyrin-Biroulet L, Brixi-Benmansour H, Mathieu N, Bouhnik Y, GETAID. Anti-TNF therapy and pregnancy in inflammatory bowel disease: A prospective cohort study from the GETAID. Gastroenterol 2011; 140: S175 [DOI: 10.1016/ S0016-5085(11)60708-7]
104. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Sie-gel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with infammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286-292; quiz e24 [PMID: 23200982 DOI: 10.1016/j.cgh.2012.11.011]
105. Mahadevan U, Martin CF, Sandler RS, Kane SV, Dubinsky M, Lewis JD, Sandborn WJ, Sands BE. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterol 2012; 14: S149